CY1120977T1 - Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι - Google Patents

Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι

Info

Publication number
CY1120977T1
CY1120977T1 CY181101308T CY181101308T CY1120977T1 CY 1120977 T1 CY1120977 T1 CY 1120977T1 CY 181101308 T CY181101308 T CY 181101308T CY 181101308 T CY181101308 T CY 181101308T CY 1120977 T1 CY1120977 T1 CY 1120977T1
Authority
CY
Cyprus
Prior art keywords
treatment
gylicogene
storage diseases
storage disease
disease type
Prior art date
Application number
CY181101308T
Other languages
Greek (el)
English (en)
Inventor
Yuan-Tsong Chen
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22818451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120977(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP07001091.3A external-priority patent/EP1782825B1/en
Application filed by Univ Duke filed Critical Univ Duke
Publication of CY1120977T1 publication Critical patent/CY1120977T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CY181101308T 2000-07-18 2018-12-07 Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι CY1120977T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21923700P 2000-07-18 2000-07-18
EP07001091.3A EP1782825B1 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage diseases type II
EP01951000A EP1301201B1 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage disease type ii
PCT/US2001/021651 WO2002005841A1 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage disease type ii
EP14167882.1A EP2767291B1 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage disease type II

Publications (1)

Publication Number Publication Date
CY1120977T1 true CY1120977T1 (el) 2019-12-11

Family

ID=22818451

Family Applications (2)

Application Number Title Priority Date Filing Date
CY181101308T CY1120977T1 (el) 2000-07-18 2018-12-07 Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
CY20201100587T CY1123084T1 (el) 2000-07-18 2020-06-24 Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20201100587T CY1123084T1 (el) 2000-07-18 2020-06-24 Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι

Country Status (17)

Country Link
US (10) US7056712B2 (enExample)
EP (4) EP3449934B1 (enExample)
JP (10) JP5113312B2 (enExample)
AT (1) ATE355075T1 (enExample)
AU (3) AU7194101A (enExample)
BR (1) BR0113006A (enExample)
CA (1) CA2416492C (enExample)
CY (2) CY1120977T1 (enExample)
DE (1) DE60126947T2 (enExample)
DK (5) DK1782825T3 (enExample)
ES (5) ES2599401T3 (enExample)
LT (3) LT2767291T (enExample)
MX (1) MXPA03000474A (enExample)
PT (5) PT3108895T (enExample)
SI (3) SI3108895T1 (enExample)
TW (1) TWI280882B (enExample)
WO (1) WO2002005841A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056712B2 (en) * 2000-07-18 2006-06-06 Duke University Treatment of glycogen storage disease type II
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
EP1436316B1 (en) * 2001-04-30 2008-01-23 ZyStor Therapeutics , Inc. Subcellular targeting of therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US6981964B2 (en) 2001-05-22 2006-01-03 Boston Scientific Scimed, Inc. Draining bodily fluids with a stent
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US6733536B1 (en) 2002-10-22 2004-05-11 Scimed Life Systems Male urethral stent device
PT1587923E (pt) 2003-01-22 2011-12-07 Univ Duke Construções melhoradas para a expressão de polipéptidos lisossomais
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
DE602005020745D1 (de) * 2004-02-10 2010-06-02 Zystor Therapeutics Inc Saure alpha-glukosidase und fragmente davon
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
EP1773401B1 (en) * 2004-06-21 2013-01-02 Medtronic, Inc. Medical systems and methods for delivering compositions to cells
AU2007322123A1 (en) * 2006-11-13 2008-05-29 Biomarin Pharmaceutical Inc. Methods for treating Pompe disease
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
WO2009137721A2 (en) 2008-05-07 2009-11-12 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
US9050333B2 (en) 2008-07-08 2015-06-09 Duke University Method of treating glycogen storage disease type III with human acid α-glucosidase
US8785168B2 (en) 2009-06-17 2014-07-22 Biomarin Pharmaceutical Inc. Formulations for lysosomal enzymes
US8809282B2 (en) 2010-05-06 2014-08-19 Duke University Method of reducing titers of antibodies specific for a therapeutic agent
JP2016514096A (ja) 2013-02-20 2016-05-19 バレリオン セラピューティクス， エルエルシー ポンぺ病の処置のための方法および組成物
JP2016523835A (ja) * 2013-05-15 2016-08-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入
JP6851964B2 (ja) 2014-09-30 2021-03-31 アミカス セラピューティックス インコーポレイテッド 炭水化物が増大している非常に強力な酸性アルファ−グルコシダーゼ
WO2016178431A1 (ja) * 2015-05-07 2016-11-10 国立大学法人 東京大学 ポリイオンコンプレックス型ポリマーソームを用いたナノリアクタとその製造方法
EP3344337A4 (en) * 2015-08-31 2019-03-06 Duke University METHOD AND COMPOSITIONS FOR TREATING CYTOPLASMATIC GLYCOGEN MEMORY DISEASES
US10940125B2 (en) 2015-09-18 2021-03-09 Duke University Methods and compositions for the treatment of steatosis-associated disorders
IL299470B2 (en) 2015-12-30 2026-05-01 Amicus Therapeutics Inc Improved acid alpha-glucosidase for the treatment of Pompe disease
KR102618519B1 (ko) 2016-03-30 2023-12-28 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
CA3019354A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Method for selection of high m6p recombinant proteins
US11253612B2 (en) 2016-04-15 2022-02-22 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type II
CN119113091A (zh) 2017-05-15 2024-12-13 阿米库斯治疗学公司 重组人类酸性α-葡萄糖苷酶
EP3684938A1 (en) 2017-09-22 2020-07-29 The Trustees of the University of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
WO2020163480A1 (en) * 2019-02-05 2020-08-13 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase and uses thereof
IT202300005733A1 (it) * 2023-03-27 2024-09-27 St Microelectronics Int Nv Circuito di comunicazione, sistema e procedimento corrispondenti

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3063911A (en) * 1961-04-03 1962-11-13 Taisho Pharmaceutical Co Ltd Acid-stable digestive enzyme preparation and process of making same
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
WO1999058691A2 (en) 1998-05-13 1999-11-18 Harbor-Ucla Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
DK2020438T3 (en) 1998-12-07 2018-07-23 Genzyme Corp Treatment of Pompe disease
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US7056712B2 (en) * 2000-07-18 2006-06-06 Duke University Treatment of glycogen storage disease type II
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
DE602005020745D1 (de) * 2004-02-10 2010-06-02 Zystor Therapeutics Inc Saure alpha-glukosidase und fragmente davon
US8470552B2 (en) 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture

Also Published As

Publication number Publication date
PT1301201E (pt) 2007-03-30
CY1123084T1 (el) 2021-10-29
SI3108895T1 (sl) 2019-01-31
DE60126947D1 (de) 2007-04-12
US20120058132A1 (en) 2012-03-08
ES2799882T3 (es) 2020-12-22
AU2010200487A1 (en) 2010-03-04
EP3108895A1 (en) 2016-12-28
JP2016056206A (ja) 2016-04-21
JP2014185187A (ja) 2014-10-02
EP3449934A1 (en) 2019-03-06
EP3449934B1 (en) 2020-05-20
US7056712B2 (en) 2006-06-06
EP2767291A3 (en) 2014-10-08
DK2767291T3 (en) 2016-12-05
US20020110551A1 (en) 2002-08-15
JP5792774B2 (ja) 2015-10-14
DK3108895T3 (en) 2018-11-26
JP2013231081A (ja) 2013-11-14
ES2277931T3 (es) 2007-08-01
HK1054690A1 (en) 2003-12-12
US20180185457A1 (en) 2018-07-05
CA2416492C (en) 2008-04-29
LT3449934T (lt) 2020-08-10
EP3108895B1 (en) 2018-09-19
DE60126947T2 (de) 2007-10-31
DK3449934T3 (da) 2020-06-29
EP2767291A2 (en) 2014-08-20
DK1301201T3 (da) 2007-04-02
SI2767291T1 (sl) 2016-11-30
HK1197656A1 (en) 2015-02-06
JP2018199721A (ja) 2018-12-20
US20050123531A1 (en) 2005-06-09
JP2017137357A (ja) 2017-08-10
JP5113312B2 (ja) 2013-01-09
EP1301201A1 (en) 2003-04-16
AU7194101A (en) 2002-01-30
HK1103363A1 (en) 2007-12-21
AU2001271941B2 (en) 2007-03-01
JP6163216B2 (ja) 2017-07-12
US8900552B2 (en) 2014-12-02
US20150004152A1 (en) 2015-01-01
US20160184410A1 (en) 2016-06-30
US20100254966A1 (en) 2010-10-07
SI3449934T1 (sl) 2020-09-30
EP1301201B1 (en) 2007-02-28
BR0113006A (pt) 2004-10-19
ES2523024T3 (es) 2014-11-20
US10792341B2 (en) 2020-10-06
PT3449934T (pt) 2020-06-25
JP2020019822A (ja) 2020-02-06
PT3108895T (pt) 2018-12-18
CA2416492A1 (en) 2002-01-24
DK1782825T3 (da) 2014-11-03
MXPA03000474A (es) 2003-10-06
US9370556B2 (en) 2016-06-21
PT2767291T (pt) 2016-10-25
US20210169996A1 (en) 2021-06-10
LT2767291T (lt) 2016-11-25
JP2018002749A (ja) 2018-01-11
JP2004503598A (ja) 2004-02-05
LT3108895T (lt) 2018-11-26
ES2700865T3 (es) 2019-02-19
US20130195834A1 (en) 2013-08-01
ATE355075T1 (de) 2006-03-15
TWI280882B (en) 2007-05-11
WO2002005841A1 (en) 2002-01-24
EP2767291B1 (en) 2016-09-14
PT1782825E (pt) 2014-11-04
US20080175833A1 (en) 2008-07-24
ES2599401T3 (es) 2017-02-01
JP2008081507A (ja) 2008-04-10
US9907839B2 (en) 2018-03-06
JP2012006953A (ja) 2012-01-12

Similar Documents

Publication Publication Date Title
CY1123084T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
NO20060971L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
IL173032A0 (en) Pyridazine derivatives and their use as therapeutic agents
BG106825A (en) Substituted oxazolidinones and their use in the field of blood coagulation
EA200401522A1 (ru) Противотуберкулёзный препарат: композиции и способы
NO2007010I1 (no) Sitagliptin, eventuelt i form av et farmasoytisk akseptabelt salt
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
IL162384A0 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
ATE530184T1 (de) Piperazinon-verbindungen als tumor- und krebsbekämpfende wirkstoffe
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
DK1294379T3 (da) En hidtil ukendt anvendelse af deferipron
EA200600374A1 (ru) Замещённые пиперидинофенилоксазолидиноны, обладающие противомикробной активностью, с повышенной in vivo эффективностью
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
ATE478688T1 (de) Verbindungen für den transfer von oligonukleotiden
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
SE0100873D0 (sv) Method of treatment
EP1782825A3 (en) Treatment of glycogen storage diseases type II
DE60313344D1 (de) Verwendung von 4-pyridylmethyl-phthalazin-derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen
EA200600318A1 (ru) ПРОИЗВОДНЫЕ 3-НИТРОПИРАЗОЛО[1,5-a]ПИРИМИДИНОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ, ЛЕКАРСТВЕННОЕ СРЕДСТВО (ВАРИАНТЫ) И СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С МОДУЛЯЦИЕЙ РЕЦЕПТОРА ГАМК(ВАРИАНТЫ)